Universitè De Montpellier

Centre Hospitalier Universitaire De Montpellier

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Inserm (Institut National De La Sante Et De La Recherche Medicale)

Horiba Abx Sas

Centre Hospitalier Et Universitaire De Montpellier

Inserm

Université De Montpellier I

Jérôme Moreaux

Alboukadel Kassambara

Bernard Klein

Guillaume Cartron

Laurie Herviou

Caroline Bret

Wafa Hassen

Giacomo Cavalli

Hugues De Boussac

Philippe Pasero

Angelos Constantinou

Rosalie Plantefeve

Guilhem Requirand

Philippe Nerin

Jean-Michel Garcia

Thierry Reme

Sébastien Raimbault

Elina Alaterre

Disclosed is a method for in vitro predicting the outcome of an individual having a multiple myeloma, including: —a) measuring the expression level of at least 2 genes encoding a ROS detoxifying (AOX) protein selected in a group including AKR1 B1, ARNT, CAT, CBR1, DHCR24, EGLN1, GLRX2, HIF1A, MGST1, MSRB1, PRDX6, SLC7A11, SOD1, SRXN1, TALDO1 and TXN and/or the expression level of at least 2 genes encoding ROS producing (ROS) protein selected in a group including CYBA, CYB5A, CYC1, NCF1B, NCF1C, NCF4, NDUFA12, NDUFS2, NDUFS8, SHC1 and UQCR10, in a biological sample obtained from the individual; —b) calculating an AOX score value and/or a ROS score value from the respective expression level(s) obtained at step a); —c) classifying the individual as having a good prognosis status or a bad prognosis status, by comparing the score value obtained at step b) with a reference score value.

Methods for the in vitro determination of the outcome and for the treatment of individuals having multiple myeloma

A method for in vitro predicting of the outcome of an individual having a multiple myeloma, including the steps of: a) measuring the expression level of at least 5 genes and/or proteins encoded by the 5 genes, the genes being selected in a group including NRP2, REEP1, SV2B, ARRB1, CACNA1G, FBLIM1, FGFR1, IRF6, ITGA9, NOVA2, PPP2R2C, SLC5A1, SORL1, SYT7 and THY1, in a biological sample obtained from the individual; b) calculating a score value from the expression level obtained at step a); c) classifying the individual as having a good prognosis status or a bad prognosis status, by comparing the score value obtained at step b) with a reference score value.

Method for the in vitro prognosis of individuals having multiple myeloma and method for the treatment thereof

The invention relates to a method for in vitro predicting the outcome of an individual having a multiple myeloma, comprising the steps of: a. measuring the expression level of genes coding for kinases, b. calculating a score value for each genes; and c. classifying the individual as having a good or a bad outcome.

Prognosis method of multiple myeloma

The present invention relates to a method of testing whether a patient suffering from arge B-cell lymphoma will respond or not to a DNA repair pathway inhibitor comprising: i) determining the expression level (ELi) of several genes Gi-Gn selected from table A in a biological sample obtained from said patient comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the DNA repair score trough the following formula (I), wherein &#x3b2;i represent the regression &#x3b2; coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=&#x2212;1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) iv) comparing the score DNARS determined at step iii) with a predetermined reference value DNARSv) and concluding that the patient will respond to the treatment when the DNARS score is higher than the predetermined reference value DNARSor concluding that the patient will not respond to the treatment when the DNARS score is lower than the predetermined reference value DNARS. 

Methods for predicting response to DNA repair pathway inhibitors in diffuse large B-cell lymphoma

The present invention relates to a method of testing whether a patient suffering from multiple myeloma will respond or not to a combination treatment consisting of at least one histone deacetylase inhibitor (HDACi) with at least one DNA methyltransferase inhibitors (DNMTi) comprising: i) determining the expression level (ELi) of several genes G-Gselected from table A in a biological sample obtained from said patient ii) comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the HADMS score trough the following formula (I) wherein &#x3b2;i represent the regression &#x3b2; coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=&#x2212;1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) iv) comparing the score HADMS determined at step iii) with a predetermined reference value HADMSv) and concluding that the patient will respond to the combination treatment when the HADMS score is higher than the predetermined reference value HADMSor concluding that the patient will not respond to the combination treatment when the HADMS score is lower than the predetermined reference value HADMS. 

Methods for predicting response to HDACi/DNMTi combination in multiple myeloma

The present invention relates to a method of testing whether a patient suffering of myeloma will respond or not to a histone deacetylase inhibitor (HDACi) comprising: determining the expression level (ELi) of several genes G-Gselected from table A in a biological sample obtained from said patient comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the HAS score trough the following formula wherein &#x3b2;i represent the regression &#x3b2; coefficient reference value for the gene Gand Ci=1 if the expression of the gene G(ELi) is higher than the predetermined reference level (ELRi) or Ci=&#x2212;1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) comparing the score HAS determined at step iii) with a predetermined reference value HASv) and concluding that the patient will respond to the HDACi when the HAS score is higher than the predetermined reference value HASor concluding that the patient will not respond to the HDACi when the HAS score is lower than the predetermined value HAS. 

Methods for predicting multiple myeloma treatment response

Growing community of inventors

Montpellier, France

Jérôme Moreaux